Synmosa Biopharma Corporation

TPEX:4114 Stock Report

Market Cap: NT$14.7b

Synmosa Biopharma Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Chih-Hui Lin

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure19yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure5yrs

Recent management updates

Recent updates

Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

Apr 04
Is Synmosa Biopharma Corporation (GTSM:4114) A Smart Pick For Income Investors?

If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Mar 08
If You Had Bought Synmosa Biopharma (GTSM:4114) Stock Three Years Ago, You Could Pocket A 22% Gain Today

Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Jan 31
Should Weakness in Synmosa Biopharma Corporation's (GTSM:4114) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?

Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Jan 05
Is Synmosa Biopharma (GTSM:4114) A Risky Investment?

Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

Dec 09
Here's Why We Don't Think Synmosa Biopharma's (GTSM:4114) Statutory Earnings Reflect Its Underlying Earnings Potential

CEO Compensation Analysis

How has Chih-Hui Lin's remuneration changed compared to Synmosa Biopharma's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023n/an/a

NT$595m

Sep 30 2023n/an/a

NT$585m

Jun 30 2023n/an/a

NT$562m

Mar 31 2023n/an/a

NT$800m

Dec 31 2022n/an/a

NT$799m

Sep 30 2022n/an/a

NT$735m

Jun 30 2022n/an/a

NT$693m

Mar 31 2022n/an/a

NT$368m

Dec 31 2021n/an/a

NT$304m

Sep 30 2021n/an/a

NT$288m

Jun 30 2021n/an/a

NT$293m

Mar 31 2021n/an/a

NT$634m

Dec 31 2020NT$5mNT$4m

NT$638m

Compensation vs Market: Insufficient data to establish whether Chih-Hui's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Insufficient data to compare Chih-Hui's compensation with company performance.

CEO

Chih-Hui Lin (40 yo)

19yrs

Tenure

NT$4,710,000

Compensation

Mr. Chih-Hui Lin serves as Chairman at Synmosa Biopharma Corporation and serves as its Director since May 16, 2019. He serves as President, Managerial officer and General Manager of the Synmosa Biopharma C...

Board Members

NamePositionTenureCompensationOwnership
Chih-Hui Lin
Chairman19yrsNT$4.71mno data
San-Chien Tu
Additional Independent Directorless than a yearno datano data
Xiang-Lang Liu
Independent Director21.3yrsNT$1.07mno data
Xiu-Mei Lin
Independent Director5yrsNT$1.19mno data
You-Peng Zhang
Representative Director5yrsNT$1.09m1.01%
NT$ 148.3m
Li-Wen Huang
Representative Director15.3yrsNT$1.09m0.96%
NT$ 141.6m
Huilan Qiu
Independent Directorless than a yearno datano data

5.0yrs

Average Tenure

41yo

Average Age

Experienced Board: 4114's board of directors are considered experienced (5 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.